Darin J. Weber Sells 17,238 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 17,238 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $2.50, for a total transaction of $43,095.00. Following the sale, the senior vice president now owns 172,432 shares of the company’s stock, valued at $431,080. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

ProKidney Price Performance

NASDAQ:PROK opened at $2.84 on Thursday. ProKidney Corp. has a 1-year low of $1.12 and a 1-year high of $13.51. The stock has a market cap of $651.33 million, a P/E ratio of -4.98 and a beta of 1.08. The firm has a 50-day moving average of $1.56 and a two-hundred day moving average of $1.80.

ProKidney (NASDAQ:PROK) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. As a group, equities analysts expect that ProKidney Corp. will post -0.65 earnings per share for the current year.

Wall Street Analyst Weigh In

PROK has been the subject of several recent research reports. Morgan Stanley started coverage on ProKidney in a report on Thursday, March 7th. They issued an “equal weight” rating and a $3.00 price target for the company. Bank of America downgraded shares of ProKidney from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 2nd.

Institutional Trading of ProKidney

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of ProKidney in the 3rd quarter valued at about $980,000. Vanguard Group Inc. bought a new stake in shares of ProKidney in the 3rd quarter valued at approximately $1,370,000. Bank of America Corp DE lifted its stake in ProKidney by 1,964,340.0% during the fourth quarter. Bank of America Corp DE now owns 196,444 shares of the company’s stock worth $1,348,000 after purchasing an additional 196,434 shares during the last quarter. Geode Capital Management LLC boosted its holdings in ProKidney by 29.5% in the fourth quarter. Geode Capital Management LLC now owns 132,808 shares of the company’s stock worth $911,000 after purchasing an additional 30,253 shares during the period. Finally, Amundi bought a new stake in ProKidney during the fourth quarter valued at $182,000. Institutional investors own 51.59% of the company’s stock.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.